SynthesisBMC cancer2025
Circulating protein levels of insulin-like growth factor 1 signaling pathway and the predisposition to colorectal carcinogenesis: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe insulin-like growth factor (IGF) family plays a critical role in cancer progression, with the insulin-like growth factor-1 receptor IGF-1Rsignificantly regulating cellular growth through specific signaling pathways. These pathways may enhance cell proliferation and colorectal cancer (CRC) advancement. Some studies suggest an association between serum IGF levels and reduced CRC risk. To further elucidate this relationship, we conducted a systematic literature review and meta-analysis investigating the association between blood IGF levels and CRC onset.
methodsA comprehensive search was conducted in PubMed, Scopus and Web of Science databases for studies published until February 15, 2025. A total of 71 eligible studies, comprising 7360 CRC cases and 15982 controls, were included. Gene expression data for IGF-1, IGF-1R, insulin receptor substrates (IRS1), IGF-2, and insulin-like growth factor-binding protein 3 (IGFBP3) were analyzed. The pooled effect estimates with 95% confidence intervals (CIs) were calculated to assess relationships between gene expression levels and CRC susceptibility. Statistical analyses were performed using STATA version 14.0 and R, version 4.4.1.
resultsThe meta-analysis demonstrated a significant association between elevated circulating IGF-1 levels and an increased risk of colorectal cancer (WMD = 11.24; 95% CI: 4.18–18.30; p = 0.002) as well as precancerous colorectal lesions (WMD = 21.35; 99% CI: 3.37–34.89; p = 0.002). Conversely, reduced IGFBP-3 levels were significantly associated with a higher CRC risk (WMD = − 138.20; 95% CI: −231.77 to − 44.64; p = 0.004). No significant association was observed for IGF-2 (WMD = − 5.40; 95% CI: −35.11 to 24.31.
conclusionsElevated IGF1 levels and reduced IGFBP3 levels are correlated with increased CRC risk, suggesting a potential role of these factors in CRC development. These findings provide insight into CRC pathogenesis and could inform future diagnostic and therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.